Tracking Immuno-Oncoloogy at SITC 2026
ONCrg is attending SITC 2026 in Phoenix, AZ. Our dedicated Ph.D. oncology analysts will be covering key clinical sessions to analyze:
🔹 Late-breaking data on next-generation IO modalities.
🔹 Key competitive shifts impacting the global oncology pipeline.
🔹 Novel multi-MOA approaches: are single molecules engineered to hit multiple targets better than combination regimens pairing two distinct agents?
With continuous advances in targeted immunotherapies, bispecific antibodies, tumor microenvironment modulation, and cell-based platforms, staying on top of early clinical efficacy signals and safety profiles is vital for strategic decision-making.
Heading to SITC 2026? Let’s connect on-site to discuss how ONCrg’s tailored CI, disease landscape evaluations, and conference intelligence can fuel your strategic goals.
Reach out to schedule a meeting with our team.
ONCrg Conference Coverage details: https://onc-rg.com/conferences/
- bispecific antibodies
- Cancer Research
- Immuno-Oncology
- SITC 2026
- MOAs
- Mechanism of Actions
- Bio Tech CI
- Pharma Strategy
- Combination Therapy
- Cell-based Platforms
- Targeted Immunotherapies
- tumor microenvironment modulation
- IO Modalities
- +10